NCT02040987View on ClinicalTrials.gov

AZD3293 Thorough QT Study in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Alzheimer's Disease
Interventions
DRUG

AZD3293

AZD3293 oral solution - one single dose (low dose).

DRUG

AZD3293

AZD3293 oral solution - one single dose (high dose).

DRUG

Placebo

Placebo oral solution - one single dose

DRUG

Moxifloxacin

Moxifloxacin tablet - one single dose

Trial Locations (1)

Unknown

Research Site, Baltimore

Sponsors

Lead Sponsor

AstraZeneca

Collaborators (1)

Parexel
All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY